Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli.

Content Provider	Europe PMC
Author	Sales, Francisco Chaves, João McMurray, Rob Loureiro, Rui Fernandes, Hélder Villanueva, Vicente
Abstract	AbstractObjectivesTo assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) in patients included in the Euro‐Esli study who had focal seizures associated with post‐stroke epilepsy (PSE).Materials and MethodsEuro‐Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments (evaluated after 3, 6 and 12 months of ESL treatment and at final follow‐up [“last visit”]) included rates of response (≥50% seizure frequency reduction), seizure freedom (no seizures since at least the prior visit) and retention. Safety/tolerability was assessed throughout ESL treatment by evaluating adverse events (AEs) and discontinuation due to AEs. A post hoc analysis was conducted of patients with PSE versus patients without PSE (“non‐PSE”).ResultsOf 1656 patients included in the analysis, 76 (4.6%) had PSE and 1580 (95.4%) had non‐PSE. Compared with non‐PSE patients, PSE patients were significantly older, had significantly shorter epilepsy duration, significantly lower total baseline seizure frequency, and were treated with significantly fewer prior and concomitant antiepileptic drugs (P < .001 for all). At the last visit, the responder rate was significantly higher in PSE versus non‐PSE patients (72.9% vs 60.6%; P = .040), as was the seizure freedom rate (48.6% vs 31.7%; P = .003). After 12 months, retention was significantly higher in PSE versus non‐PSE patients (87.8% vs 77.4%; P = .035). The incidence of AEs was similar for PSE versus non‐PSE patients (36.0% vs 35.8%; P = .966).ConclusionsThese findings suggest that ESL may be an effective and well‐tolerated treatment option for patients with focal seizures due to PSE.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7754143&blobtype=pdf
Page Count	11
ISSN	00016314
Journal	Acta Neurologica Scandinavica [Acta Neurol Scand]
Volume Number	142
DOI	10.1111/ane.13323
PubMed Central reference number	PMC7754143
Issue Number	6
PubMed reference number	32691850
e-ISSN	16000404
Language	English
Publisher	John Wiley and Sons Inc.
Publisher Date	2020-08-12
Publisher Place	Hoboken
Access Restriction	Open
Rights License	This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2020 BIAL ‐ Portela & Ca, S.A. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd
Subject Keyword	Epilepsy eslicarbazepine acetate seizures stroke
Content Type	Text
Resource Type	Article
Subject	Neurology Neurology (clinical)